

#1
RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

No. of Claims After Amendment			Most Claims Previously Paid		Extra Claims				Additional Fee
A. Total Claims	116	-	116	=	0	x	\$18	=	0.00
B. Ind. Claims	16	-	16	=	0	x	\$84	=	0.00
C. If amended to contain multiple dependent claims, add \$260							\$280	=	0.00
D. Total Amendment Fee (Total of A, B & C)								=	0.00
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	0.00
F. Total Amendment Fee (D minus E)								=	0.00

The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. **A duplicate copy of this sheet is enclosed.**


Respectfully submitted,

By: Shelley P. Eberle
Shelley P. Eberle
Registration No. 31,411

REED & ASSOCIATES
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

June 28, 2002
Date Signature



Atty Dkt No. 0300-0014
PATENT

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Steven E. Cwirla et al.

Serial No.: 09/620,091

Group Art Unit: 1634

Filing Date: July 20, 2000

Examiner: Bradley L. SISSON

COPY OF PAPERS
ORIGINALLY FILED

Title: COMPOUNDS HAVING AFFINITY FOR THE GRANULOCYTE-COLONY
STIMULATING FACTOR RECEPTOR (G-CSFR) AND ASSOCIATED USES

AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, DC 20231

Sir:

This is in response to a first Office Action mailed on March 28, 2002. *As this response is being filed within the three-month shortened statutory period set for response, no extension of time is necessary.* Applicants respectfully request entry of the following amendments and reconsideration of the application in light of the following amendments and remarks.

AMENDMENTS

IN THE SPECIFICATION

Delete the paragraph at page 5, lines 8-10, and replace with the following:

-- Figures 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 1I, 1J and 1K provide the sequences of representative peptide chains contained within the compounds of the invention. --

a1